2. Signaling Pathways
  3. JAK/STAT Signaling
    Stem Cell/Wnt
  4. STAT

STAT

STAT

Related Products

PDF 1.6 MB

STAT is a family of cytoplasmic protein that regulates many aspects of growth, survival and differentiation in cells. The transcription factors of this family are activated by Janus kinase and dysregulation of this pathway is frequently observed in primary tumours and leads to increased angiogenesis, enhanced survival of tumours and immunosuppression. Gene knockout studies have provided evidence that STAT proteins are involved in the development and function of the immune system and play a role in maintaining immune tolerance and tumour surveillance. STAT proteins were originally described as latent cytoplasmic transcription factors that require phosphorylation for nuclear retention. The unphosphorylated STAT proteins shuttle between cytosol and the nucleus waiting for its activation signal. Once the activated transcription factor reaches the nucleus, it binds to consensus DNA-recognition motif called gamma-activated sites (GAS) in the promoter region of cytokine-inducible genes and activates transcription of these genes.

STAT Isoform Specific Products:

STAT Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-164469
    CHMFL-48
    		Inhibitor
    CHMFL-48 is an orally active BCR-ABL kinase inhibitor targeting both wild-type (wt) and various imatinib-resistant mutants. The IC50 values for CHMFL-48 against ABL wild-type and ABL T315I mutant are 1 nM and 0.8 nM, respectively. CHMFL-48 exerts its effects by blocking the autophosphorylation of BCR-ABL wild-type and mutant forms, which impacts downstream signaling mediators such as STAT5 and CRKL, leading to cell cycle arrest and induction of apoptosis. CHMFL-48 holds potential for research into chronic myeloid leukemia (CML).
    CHMFL-48
  • HY-118081
    inS3-54-A26
    		Inhibitor
    inS3-54-A26 is a STAT3 inhibitor. inS3-54-A26 has a toxic IC50 of 4.0 μM for non-cancerous lung fibroblasts.
    inS3-54-A26
  • HY-14944R
    Homoharringtonine (Standard)
    		Inhibitor
    Homoharringtonine (Standard) is the analytical standard of Homoharringtonine. This product is intended for research and analytical applications. Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation.
    Homoharringtonine (Standard)
  • HY-164473
    DETD-35
    		Inhibitor
    DETD-35 is an inhibitor of the MEK-ERK, Akt, and STAT3 signaling pathways, which promotes cancer cell apoptosis (Apoptosis) and reduces cancer cell resistance to Vemurafenib (HY-12057). The IC50 values of DETD-35 against wild-type and mutant melanoma cell lines B16-F10, MeWo, SK-MEL-2, A2058c, and A375c are 2.7, 6.0, 3.9, 3.1, and 2.5 μM, respectively. DETD-35 holds promise for research in the field of anti-melanoma therapy.
    DETD-35
  • HY-13072B
    Cenisertib benzoate
    		Inhibitor
    Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib benzoate inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia.
    Cenisertib benzoate
  • HY-P10099
    STAT3-IN-21, cell-permeable, negative control
    STAT3-IN-21, cell-permeable, negative control, a peptide, is a negative control for Stat3 activity detection.
    STAT3-IN-21, cell-permeable, negative control
  • HY-122166
    Histamine receptors inhibitor 1
    Histamine receptors inhibitor 1 (compound 303) is an inhibitor of H1R or H4R that can be used in the research of inflammatory, autoimmune, allergic, and ocular.
    Histamine receptors inhibitor 1
  • HY-171038
    STAT3-IN-39
    		Inhibitor
    STAT3-IN-39 (compound 10K) is an orally active STAT3 inhibitor that exhibits excellent inhibitory activity against STAT3 phosphorylation, with an IC50 of 0.47 μM in NIH-3T3 cells. STAT3-IN-39 inhibits the TGF-β1-induced fibrotic response and blocks the epithelial-mesenchymal transition in A549. STAT3-IN-39 can be utilized in research related to idiopathic pulmonary fibrosis.
    STAT3-IN-39
  • HY-N0193R
    Artesunate (Standard)
    		Inhibitor
    Artesunate (Standard) is the analytical standard of Artesunate. This product is intended for research and analytical applications. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).
    Artesunate (Standard)
  • HY-B1436R
    Nifuroxazide (Standard)
    		Inhibitor
    Nifuroxazide (Standard) is the analytical standard of Nifuroxazide. This product is intended for research and analytical applications. Nifuroxazide is an effective inhibitor of STAT3, also exerts potent anti-tumor and anti-metastasis activity.
    Nifuroxazide (Standard)
  • HY-N0177R
    Diosgenin (Standard)
    		Inhibitor
    Diosgenin (Standard) is the analytical standard of Diosgenin. This product is intended for research and analytical applications. Diosgenin, a steroidal saponin, can inhibit STAT3 signaling pathway. Diosgenin is an exogenous activator of Pdia3/ERp57. Diosgenin inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression.
    Diosgenin (Standard)
  • HY-N0897R
    Corylifol A (Standard)
    		Inhibitor
    Corylifol A (Standard) is the analytical standard of Corylifol A. This product is intended for research and analytical applications. Corylifol A inhibits IL-6-induced STAT3 activation and phosphorylation, with an IC50 of 0.81 μM.
    Corylifol A (Standard)
  • HY-164551
    YLL545
    		Inhibitor
    YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2/KDR/Flk-1) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2/KDR/Flk-1 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC). YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth.
    YLL545
  • HY-120376
    XZH-5
    		Inhibitor
    XZH-5 inhibits the phosphorylation of STAT3 and results in the induction of apoptosis and reduction of colony forming ability.
    XZH-5
  • HY-W369099
    HJC0152 free base
    		Inhibitor
    HJC0152 (free base) is an orally active and potent inhibitor of STAT3. HJC0152 (free base) inhibits cell cycle progression and induces apoptosis. HJC0152 (free base) significantly suppresses MDA-MB-231 xenograft tumor growth in mice.
    HJC0152 free base
  • HY-120604
    BVB808
    BVB808 (NVP_BVB808) is a selective JAK2 inhibitor with approximately 10-fold selectivity for JAK2 over other JAK family members (such as JAK1, JAK3 or TYK2) in vitro. BVB808 inhibits the activity of JAK2 and reduces the phosphorylation of STAT5, thereby blocking the JAK2-dependent cell proliferation and survival signaling pathways. BVB808 can be used in cancer research.
    BVB808
  • HY-W653999
    Glycodeoxycholic acid-d5
    		Activator
    Glycodeoxycholic acid-d5 is deuterium labeled Glycodeoxycholic Acid. Glycodeoxycholic Acid is a natural product found in Streptomyces nigricans, Trypanosoma brucei and C. elegans. Glycodeoxycholic Acid induces hepatocyte necrosis and autophagy in patients with obstructive cholestasis.
    Glycodeoxycholic acid-d<sub>5</sub>
  • HY-N0407R
    Picroside I (Standard)
    		Inhibitor
    Picroside I (Standard) is the analytical standard of Picroside I. This product is intended for research and analytical applications. Picroside I is the major ingredient of Picrorhiza scrophulariiflora. Picrorhiza scrophulariiflora is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II. Picroside I is a promising agent for the management of asthma. Picroside I reduces the inflammation significantly at its higher dose. Picroside I also downregulates pSTAT6 and GATA3 expressions. Picroside I dose-dependently increases the serum levels of IFN-γ.
    Picroside I (Standard)
  • HY-B0294R
    Flubendazole (Standard)
    		Inhibitor
    Flubendazole (Standard) is the analytical standard of Flubendazole. This product is intended for research and analytical applications. Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites.
    Flubendazole (Standard)
  • HY-119009
    TM-233
    		Inhibitor
    TM-233 is an inhibitor of the JAK/STAT and NF-κB signaling pathways, exhibiting significant antitumor activity. TM-233 reduces the expression of the anti-apoptotic protein Mcl-1 by inhibiting the phosphorylation of JAK2 and STAT3, and regulates its transcription by directly binding to the Mcl-1 gene promoter. Additionally, TM-233 prevents the translocation of NF-κB from the cytoplasm to the nucleus by inhibiting its DNA-binding activity, thereby reducing nuclear NF-κB expression. TM-233 shows potential in overcoming Bortezomib (HY-10227) resistance and can be applied in research related to multiple myeloma.
    TM-233
Cat. No. Product Name / Synonyms Application Reactivity
STAT Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.